Seizert Capital Partners LLC Has $62.14 Million Position in Amgen Inc. (NASDAQ:AMGN)

Seizert Capital Partners LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.7% during the third quarter, HoldingsChannel reports. The fund owned 192,842 shares of the medical research company’s stock after buying an additional 1,403 shares during the quarter. Amgen comprises about 2.8% of Seizert Capital Partners LLC’s portfolio, making the stock its 4th largest holding. Seizert Capital Partners LLC’s holdings in Amgen were worth $62,136,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Capital Performance Advisors LLP acquired a new position in shares of Amgen during the third quarter worth $25,000. Hershey Financial Advisers LLC acquired a new position in Amgen during the 2nd quarter worth about $30,000. nVerses Capital LLC bought a new stake in shares of Amgen in the 2nd quarter valued at about $31,000. Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen in the second quarter valued at about $33,000. Finally, Matrix Trust Co bought a new position in shares of Amgen during the third quarter worth about $36,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several analyst reports. TD Cowen upped their target price on Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a report on Monday, October 21st. StockNews.com upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Citigroup assumed coverage on shares of Amgen in a research note on Thursday. They set a “neutral” rating and a $335.00 target price for the company. Wells Fargo & Company downgraded Amgen from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $320.00 to $335.00 in a report on Wednesday, August 7th. Finally, William Blair reiterated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and an average target price of $333.57.

Amgen Trading Down 4.2 %

AMGN opened at $283.61 on Friday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The company’s 50-day moving average is $320.85 and its 200 day moving average is $318.36. The firm has a market capitalization of $152.45 billion, a PE ratio of 36.31, a P/E/G ratio of 2.69 and a beta of 0.60. Amgen Inc. has a fifty-two week low of $260.52 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business’s revenue was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.96 EPS. As a group, research analysts predict that Amgen Inc. will post 19.51 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.17%. The ex-dividend date is Monday, November 18th. Amgen’s dividend payout ratio is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.